330 related articles for article (PubMed ID: 30907747)
1. Aspirin blocks formation of metastatic intravascular niches by inhibiting platelet-derived COX-1/thromboxane A2.
Lucotti S; Cerutti C; Soyer M; Gil-Bernabé AM; Gomes AL; Allen PD; Smart S; Markelc B; Watson K; Armstrong PC; Mitchell JA; Warner TD; Ridley AJ; Muschel RJ
J Clin Invest; 2019 Mar; 129(5):1845-1862. PubMed ID: 30907747
[TBL] [Abstract][Full Text] [Related]
2. Low-dose Aspirin prevents hypertension and cardiac fibrosis when thromboxane A
D'Agostino I; Tacconelli S; Bruno A; Contursi A; Mucci L; Hu X; Xie Y; Chakraborty R; Jain K; Sacco A; Zucchelli M; Landolfi R; Dovizio M; Falcone L; Ballerini P; Hwa J; Patrignani P
Pharmacol Res; 2021 Aug; 170():105744. PubMed ID: 34182131
[TBL] [Abstract][Full Text] [Related]
3. Profiling the eicosanoid networks that underlie the anti- and pro-thrombotic effects of aspirin.
Crescente M; Armstrong PC; Kirkby NS; Edin ML; Chan MV; Lih FB; Jiao J; Maffucci T; Allan HE; Mein CA; Gaston-Massuet C; Cottrell GS; Mitchell JA; Zeldin DC; Herschman HR; Warner TD
FASEB J; 2020 Aug; 34(8):10027-10040. PubMed ID: 32592197
[TBL] [Abstract][Full Text] [Related]
4. Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy.
Warner TD; Nylander S; Whatling C
Br J Clin Pharmacol; 2011 Oct; 72(4):619-33. PubMed ID: 21320154
[TBL] [Abstract][Full Text] [Related]
5. COX-2 is not involved in thromboxane biosynthesis by activated human platelets.
Patrignani P; Sciulli MG; Manarini S; Santini G; Cerletti C; Evangelista V
J Physiol Pharmacol; 1999 Dec; 50(4):661-7. PubMed ID: 10639016
[TBL] [Abstract][Full Text] [Related]
6. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis.
Schrör K
Semin Thromb Hemost; 1997; 23(4):349-56. PubMed ID: 9263351
[TBL] [Abstract][Full Text] [Related]
7. Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells.
Guillem-Llobat P; Dovizio M; Bruno A; Ricciotti E; Cufino V; Sacco A; Grande R; Alberti S; Arena V; Cirillo M; Patrono C; FitzGerald GA; Steinhilber D; Sgambato A; Patrignani P
Oncotarget; 2016 May; 7(22):32462-77. PubMed ID: 27074574
[TBL] [Abstract][Full Text] [Related]
8. Persistent production of platelet thromboxane A2 in patients chronically treated with aspirin.
Pulcinelli FM; Riondino S; Celestini A; Pignatelli P; Trifirò E; Di Renzo L; Violi F
J Thromb Haemost; 2005 Dec; 3(12):2784-9. PubMed ID: 16359516
[TBL] [Abstract][Full Text] [Related]
9. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets.
Watts IS; Wharton KA; White BP; Lumley P
Br J Pharmacol; 1991 Feb; 102(2):497-505. PubMed ID: 1826620
[TBL] [Abstract][Full Text] [Related]
10. Antiplatelet effect of catechol is related to inhibition of cyclooxygenase, reactive oxygen species, ERK/p38 signaling and thromboxane A2 production.
Chang MC; Chang HH; Wang TM; Chan CP; Lin BR; Yeung SY; Yeh CY; Cheng RH; Jeng JH
PLoS One; 2014; 9(8):e104310. PubMed ID: 25122505
[TBL] [Abstract][Full Text] [Related]
11. Piperine inhibits the activities of platelet cytosolic phospholipase A2 and thromboxane A2 synthase without affecting cyclooxygenase-1 activity: different mechanisms of action are involved in the inhibition of platelet aggregation and macrophage inflammatory response.
Son DJ; Akiba S; Hong JT; Yun YP; Hwang SY; Park YH; Lee SE
Nutrients; 2014 Aug; 6(8):3336-52. PubMed ID: 25153972
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of aspirin resistance.
Floyd CN; Ferro A
Pharmacol Ther; 2014 Jan; 141(1):69-78. PubMed ID: 23993980
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacology of cyclooxygenase inhibition and pharmacodynamic interaction with aspirin by floctafenine in Thai healthy subjects.
Maenthaisong R; Tacconelli S; Sritara P; Del Boccio P; Di Francesco L; Sacchetta P; Archararit N; Aryurachai K; Patrignani P; Suthisisang C
Int J Immunopathol Pharmacol; 2013; 26(2):403-17. PubMed ID: 23755755
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, pharmacological characterization, and docking analysis of a novel family of diarylisoxazoles as highly selective cyclooxygenase-1 (COX-1) inhibitors.
Vitale P; Tacconelli S; Perrone MG; Malerba P; Simone L; Scilimati A; Lavecchia A; Dovizio M; Marcantoni E; Bruno A; Patrignani P
J Med Chem; 2013 Jun; 56(11):4277-99. PubMed ID: 23651359
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of arachidonic acid induced-aggregation of rabbit platelets with CV-4151 (isbogrel), a selective thromboxane A2 (TXA2) synthase inhibitor: modulation of the antiplatelet action and prostanoid metabolism by rat aortic rings.
Terashita Z; Imura Y; Nishikawa K
J Lipid Mediat Cell Signal; 1996 Jan; 13(1):1-8. PubMed ID: 8821806
[TBL] [Abstract][Full Text] [Related]
16. Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin.
Guthikonda S; Lev EI; Patel R; DeLao T; Bergeron AL; Dong JF; Kleiman NS
J Thromb Haemost; 2007 Mar; 5(3):490-6. PubMed ID: 17319904
[TBL] [Abstract][Full Text] [Related]
17. De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin.
Evangelista V; Manarini S; Di Santo A; Capone ML; Ricciotti E; Di Francesco L; Tacconelli S; Sacchetti A; D'Angelo S; Scilimati A; Sciulli MG; Patrignani P
Circ Res; 2006 Mar; 98(5):593-5. PubMed ID: 16484611
[TBL] [Abstract][Full Text] [Related]
18. Difference of (Ca2+)i movements in platelets stimulated by thrombin and TRAP: the involvement of alpha(IIb)beta3-mediated TXA2 synthesis.
Aoki T; Tomiyama Y; Honda S; Senzaki K; Tanaka A; Okubo M; Takahashi F; Takasugi H; Seki J
Thromb Haemost; 1998 Jun; 79(6):1184-90. PubMed ID: 9657446
[TBL] [Abstract][Full Text] [Related]
19. Aspirin and coronary artery disease.
Maree AO; Fitzgerald DJ
Thromb Haemost; 2004 Dec; 92(6):1175-81. PubMed ID: 15583721
[TBL] [Abstract][Full Text] [Related]
20. Variable platelet response to aspirin and clopidogrel in atherothrombotic disease.
Maree AO; Fitzgerald DJ
Circulation; 2007 Apr; 115(16):2196-207. PubMed ID: 17452618
[No Abstract] [Full Text] [Related]
[Next] [New Search]
